These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20021664)

  • 1. Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration.
    Shi L; Ascher-Svanum H; Chiang YJ; Zhao Y; Fonseca V; Winstead D
    BMC Psychiatry; 2009 Dec; 9():80. PubMed ID: 20021664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population.
    Hsu C; Ried LD; Bengtson MA; Garman PM; McConkey JR; Rahnavard F
    J Am Pharm Assoc (2003); 2008; 48(3):393-400. PubMed ID: 18595825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics.
    Weissman EM; Zhu CW; Schooler NR; Goetz RR; Essock SM
    J Clin Psychiatry; 2006 Sep; 67(9):1323-6. PubMed ID: 17017817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
    Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
    Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Metabolic testing rates after initiation of antipsychotic treatment in persons initially treated by conventional mood-stabilizers].
    Verdoux H; Gaudron Y; Auleley GR; Deligne J; Blum-Boisgard C; Thiébaut A; Tournier M
    Encephale; 2013 May; 39 Suppl 1():S22-8. PubMed ID: 23246328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance.
    Moeller KE; Rigler SK; Mayorga A; Nazir N; Shireman TI
    Schizophr Res; 2011 Mar; 126(1-3):117-23. PubMed ID: 21168994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data.
    Morrato EH; Newcomer JW; Allen RR; Valuck RJ
    J Clin Psychiatry; 2008 Feb; 69(2):316-22. PubMed ID: 18251625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring metabolic side effects when initiating treatment with second-generation antipsychotic medication.
    Weissman E; Jackson C; Schooler N; Goetz R; Essock S
    Clin Schizophr Relat Psychoses; 2012 Jan; 5(4):201-7. PubMed ID: 22182457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender differences in antipsychotics prescribed to veterans with serious mental illness.
    Schwartz E; Charlotte M; Slade E; Medoff D; Li L; Dixon L; Kilbourne A; Kreyenbuhl J
    Gen Hosp Psychiatry; 2015; 37(4):347-51. PubMed ID: 25936673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
    Van Dorn RA; Andel R; Boaz TL; Desmarais SL; Chandler K; Becker MA; Howe A
    J Clin Psychiatry; 2011 Apr; 72(4):502-8. PubMed ID: 21527125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India.
    Pallava A; Chadda RK; Sood M; Lakshmy R
    Nord J Psychiatry; 2012 Jun; 66(3):215-21. PubMed ID: 22017264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.
    Correll CU; Robinson DG; Schooler NR; Brunette MF; Mueser KT; Rosenheck RA; Marcy P; Addington J; Estroff SE; Robinson J; Penn DL; Azrin S; Goldstein A; Severe J; Heinssen R; Kane JM
    JAMA Psychiatry; 2014 Dec; 71(12):1350-63. PubMed ID: 25321337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse.
    Lefebvre P; Muser E; Joshi K; DerSarkissian M; Bhak RH; Duh MS; Shiner B; Young-Xu Y
    Clin Ther; 2017 Jul; 39(7):1380-1395.e4. PubMed ID: 28641996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of monitoring for glucose and lipid dysregulation in adult Medi-Cal patients newly started on antipsychotics.
    Barnett M; VonMuenster S; Wehring H; Popish S; McDonald K; Walker VM; Perry P
    Ann Clin Psychiatry; 2010 Feb; 22(1):9-18. PubMed ID: 20196978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors in second-generation antipsychotic switching patterns in a national sample of older veterans with schizophrenia.
    Dassori AM; Copeland LA; Zeber JE; Miller AL
    Psychiatr Serv; 2011 Jan; 62(1):47-53. PubMed ID: 21209299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.
    Morrato EH; Druss B; Hartung DM; Valuck RJ; Allen R; Campagna E; Newcomer JW
    Arch Gen Psychiatry; 2010 Jan; 67(1):17-24. PubMed ID: 20048219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.
    Misiak B; Frydecka D; Łaczmański Ł; Ślęzak R; Kiejna A
    Eur J Clin Pharmacol; 2014 Dec; 70(12):1433-41. PubMed ID: 25291992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-label use of second generation antipsychotics for post-traumatic stress disorder in the Department of Veterans Affairs: time trends and sociodemographic, comorbidity, and regional correlates.
    Bauer MS; Lee A; Li M; Bajor L; Rasmusson A; Kazis LE
    Pharmacoepidemiol Drug Saf; 2014 Jan; 23(1):77-86. PubMed ID: 23996688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.